Israel-based pharmaceutical company NeuroDerm has reported positive results from a double-blind, placebo controlled, dose-escalation Phase I study of its levodopa / carbidopa liquid formula for the treatment of Parkinson’s disease.

Administered continuously sub-cutaneously through a patch pump, the ND0612 formula is designed to improve pharmacokinetic profile, maintain stable therapeutic levodopa plasma concentrations and ameliorate motor fluctuations and non-motor complications in Parkinson’s disease.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The pharmacokinetic trial conducted in young, healthy volunteers, had shown ND0612 to be safe and tolerable in all of the tested doses.

"ND0612 is designed to improve pharmacokinetic profile, maintain stable therapeutic levodopa plasma concentrations and ameliorate motor fluctuations and non-motor complications in Parkinson’s disease."

NeuroDerm said success in its first Phase I trial means that clinically significant steady state levodopa concentrations can, for the first time, be maintained in a practical manner both day and night.

"With ND0612, steady state levodopa levels, the elusive holy grail of Parkinson’s levodopa therapy, should be available to all PD patients," the company said.

"Moreover, as ND0612 bypasses the gastrointestinal tract, steady state levodopa levels should be little influenced by intestinal absorption or oral ingestion of food or drugs."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company’s products also include ND0611 for the treatment of Parkinson’s disease and ND0801, a combination patch, for the treatment of attention deficit disorder (ADD) / attention deficit hyperactivity disorder (ADHD).

The company said that its programmes focused on other diseases, including schizophrenia and Alzheimer’s disease, are in different stages of development.